Boccard is developing a multi-bioreactor installation to support fermentation scale-up from 50 to 5,000 L. Independent and cascade operating modes combine with integrated automation to support process development and larger-scale production.
As cosmetics production scales up, increasing the capacity of individual pieces of equipment is no longer enough. This is because automation, production flexibility, efficient material and product flows, effective CIP cleaning, and the integration of all process stages into a single system become increasingly important.
Tatra Spring, a cosmetics manufacturer belonging to the international Intercos Group, faced the challenge of moving from production based on standalone equipment to a fully integrated production environment.
Discover the key topics from Bioreactors Open Days 2026: 50 L, 500 L, and 5,000 L bioreactors, bioprocess scale-up, and biomanufacturing automation.
Discover how monoclonal antibodies work, the conditions they can help treat and how they are produced at scale. Explore recent clinical advances and Boccard’s capabilities in process equipment, utilities integration and GMP project delivery.
Neurological biologics require scalable cell culture, purification, clean utilities and GMP-ready facilities for reliable commercial production at global scale.
An unusual increase in caustic solution consumption was detected at a CIP station. Thanks to historical data in Track Advance® and Boccard’s process expertise, the source of the deviation was identified and its impact quantified; the avoided excess consumption was estimated at 255 m³/year.
As demand for immunoglobulin therapies grows across rare autoimmune diseases, manufacturers must expand plasma fractionation capacity while maintaining strict GMP and viral safety standards. This case study shows how Boccard delivered a large-scale, integrated immunoglobulin production facility designed to support long-term IVIg supply.
Modern process solutions enable the safe, efficient, and GMP-compliant production of oncology drugs. Thanks to advanced pharmaceutical technologies, it is possible to scale up production while maintaining the highest quality and full process control.
As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.
As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.
Nous serons heureux de répondre à vos demandes concernant nos offres marchés, solutions ou services. Pour nous aider à mieux vous répondre, merci de préciser votre besoin : devis, projet, services, demande de contact ou autre.
